[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Post covid brain disorders", "description": "42%increased chance of developing a neuro problem after covid, equating to 7% of those infected.\n\nDr. Al-Aly\n\nOverall, COVID-19 has contributed to more than 40 million new cases of neurological disorders worldwide\n\nLong-term neurologic outcomes of COVID-19\n\nhttps://www.nature.com/articles/s41591-022-02001-z\n\nhttps://newatlas.com/health-wellbeing/mild-covid-risk-brain-neurological-problems/\n\nhttps://medicine.wustl.edu/news/covid-19-infections-increase-risk-of-long-term-brain-problems/\n\nComprehensive evaluation of postacute neurologic sequelae at 1 year\n\nNational healthcare databases of the US Department of Veterans Affairs\n\nCovid cohort = 154,068\n\n(nonhospitalized, hospitalized and admitted to intensive care)\n\nContemporary controls = 5,638,795\n\nHistorical controls = 5,859,621 (2017 data)\n\nAverage age of 61\n\nEstimate risks and burdens of incident neurologic disorders at 12 months following acute SARS-CoV-2 infection\n\nLongitudinal observational study design\n\nMarch 2020 through January 2021\n\n(predates delta, omicron and other COVID variants)\n\nResults\n\nIn the postacute phase of COVID-19, there was increased risk of an array of incident neurologic sequelae\n\nIschemic and hemorrhagic stroke\n\nTIA\n\nCognition and memory disorders\n\nPeripheral nervous system disorders\n\nEpisodic disorders (e.g. migraine, seizures)\n\nExtrapyramidal and movement disorders\n\nMental health disorders, (anxiety depression psychosis)\n\nMusculoskeletal disorders\n\nSensory disorders\n\nGuillain\u2013Barr\u00e9 syndrome\n\nEncephalitis or encephalopathy\n\nHeadaches\n\nHazard ratio of any neurologic sequela\n\n1.42 (1.38 to 1.47)\n\nBurden\n\n70.69 (63.54 to 78.01) per 1,000 persons at 12 months\n\nOr, 7.069%\n\nThe risks and burdens were elevated even in people who did not require hospitalization during acute COVID-19\n\nRisks and burdens increased according to the severity of the acute infection,\n\nfrom nonhospitalized to hospitalized to intensive care\n\nDizzynes\n\nTaken together, our results provide evidence of increased risk of long-term neurologic disorders in people who had COVID-19.\n\nIncident neurologic outcomes in COVID-19 versus contemporary control\n\nCerebrovascular disorders (at 12 months)\n\nIschemic stroke HR 1.50, burden 3.40 per 1,000 \n\nTransient ischemic attacks HR 1.62, burden 2.03 \n\nHemorrhagic stroke HR 2.19, burden 0.21\n\nCerebral venous thrombosis HR 2.69, burden 0.05\n\nComposite of these cerebrovascular outcomes were HR 1.56, burden 4.92\n\nCognition and memory\n\nRisks of memory problems HR 1.77, burden 10.07\n\nAlzheimer\u2019s disease HR 2.03, burden 1.65\n\nComposite of these cognition and memory outcomes were HR 1.80, Burden 10.35\n\nDisorders of peripheral nerves\n\nPeripheral neuropathy HR 1.34, burden 5.64\n\nParesthesia HR 1.32, burden 2.89\n\nDysautonomia HR 1.30, burden 1.60\n\nBell\u2019s palsy HR 1.48, burden 0.32\n\nComposite of these disorders of peripheral nerves were HR 1.34, burden 8.64\n\nEpisodic disorders\n\nMigraine, epilepsy and seizures, headache disorders\n\nComposite of these episodic disorders were HR 1.32, burden 4.75\n\nExtrapyramidal and movement disorders\n\nAbnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus\n\nComposite of these extrapyramidal and movement disorders were HR 1.42, burden 3.98\n\n\nMental health disorders\n\nMajor depressive disorders, stress and adjustment disorders, anxiety disorders, psychotic disorders\n\nComposite of these mental health disorders were HR 1.43, burden 25.00\n\nMusculoskeletal disorders\n\nJoint pain, myalgia, myopathy\n\nComposite of these musculoskeletal disorders were HR 1.45, burden 40.09\n\nSensory disorders\n\nHearing abnormalities, tinnitus, vision abnormalities, loss of smell, loss of taste\n\nComposite of these sensory disorders were HR 1.25, burden 17.03 \n\nOther neurologic or related disorders\n\nDizziness, somnolence, Guillain\u2013Barr\u00e9 syndrome, encephalitis or encephalopathy, transverse myelitis\n\nComposite of these other neurologic or related disorders were HR 1.46, burden 7.37\n\nComposite outcome of any neurologic disorder\n\nCompared with the contemporary control group, there was increased risk and burden of any neurologic outcome\n\nHR 1.42, burden 70.69\n\nDr. Al-Aly\nIt doesn\u2019t matter if you are young or old, female or male, or what your race is. It doesn\u2019t matter if you smoked or not, or if you had other unhealthy habits or conditions.", "link": "https://www.youtube.com/watch?v=yF4PebYeYpU", "date_published": "2022-09-26 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Post covid Alzheimer's", "description": "69% higher risk of Alzheimer's for older COVID survivors\n\nhttps://www.cidrap.umn.edu/news-perspective/2022/09/possible-69-higher-risk-alzheimers-older-covid-survivors\n\nOlder COVID-19 survivors,\n\n69% higher risk of developing Alzheimer's disease,\n\nwithin 1 year of infection\n\nMedical records of 6,245,282 \n\n65 years and older\n\nMedical visits but no previous diagnosis of Alzheimer's disease\n\nFebruary 2020 to May 2021\n\n410,748 participants tested positive for COVID-19\n\n5,834,534 did not test positive\n\nCOVID-19 survivors had a 69% higher risk of a new diagnosis of Alzheimer's disease within 1 year of infection than their uninfected peers\n\nHazard ratio 1.69; 95% (1.53 to 1.72)\n\nMost at risk\n\nAges 85 and older, HR = 1.89\n\nWomen, HR = 1.82\n\nAssociation of COVID-19 with New-Onset Alzheimer\u2019s Disease\n\nhttps://content.iospress.com/articles/journal-of-alzheimers-disease/jad220717\n\nJournal of Alzheimer's Disease, vol. 89, no. 2, pp. 411-414, 2022\n\n13th September 2022\n\nInfectious etiology of Alzheimer\u2019s disease, postulated for decades\n\nSo, is SARS-CoV-2 infection associated with increased risk for Alzheimer\u2019s disease?\n\nRetrospective cohort study\n\nN = 6,245,282 older adults (age \u226565 years),\n\nPeople with COVID-19 were at significantly increased risk for new diagnosis of Alzheimer\u2019s disease\n\nWithin 360 days after the initial COVID-19 diagnosis \n\nPropensity-score matching\n\nCOVID-19 cohort = 0.68%\n\nnon-COVID-19 cohort = 0.35%\n\n(hazard ratio or HR:1.69)\n\nTriNetX Analytics Platform\n\nde-identified electronic health records\n\nOver 95 million patients\n\nInpatient and outpatient visits\n\n68 health care organizations\n\n28% of the US population\n\n50 states, covering diverse geographic, age, race/ethnic, income, and insurance groups \n\nOur findings call for research to understand the underlying mechanisms and for continuous surveillance of long-term impacts of COVID-19 on Alzheimer\u2019s disease\n\nNot clear whether COVID-19 triggers or accelerates development of Alzheimer's disease\n\nSARS-CoV-2 has been associated with inflammation and central nervous system disorders\n\nPrior infections, especially viral infections, and inflammation\n\nDr. Pamela Davis\n\nWe thought we had turned some of the tide on it by reducing general risk factors such as hypertension, heart disease, obesity and a sedentary lifestyle\n\nNow, so many people in the U.S. have had COVID and the long-term consequences of COVID are still emerging.\n\nIt is important to continue to monitor the impact of this disease on future disability\n\nPlan to continue studying the potential effects of COVID-19 on Alzheimer's,\n\nand other neurodegenerative diseases,\n\nwhether certain populations may be especially vulnerable\n\nAssess, any drugs could be repurposed to treat COVID-19's long-term effects", "link": "https://www.youtube.com/watch?v=M5ExGpJS_PA", "date_published": "2022-09-25 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]